- Market Capitalization, $K 1,807,034
- Shares Outstanding, K 58,048
- Annual Sales, $ 42,880 K
- Annual Income, $ -37,970 K
- 60-Month Beta 2.15
- Price/Sales 40.12
- Price/Cash Flow N/A
- Price/Book 27.80
|Period||Period Low||Period High||Performance|
| || |
+21.74 (+231.96%)since 11/11/19
| || |
+23.40 (+303.96%)since 09/11/19
| || |
+21.00 (+207.97%)since 12/11/18
Chemocentryx Inc (NASDAQ:CCXI) traded in a range yesterday that spanned from a low of $28.00 to a high of $29.89. Yesterday, the shares fell 3.4%, which took the trading range below the 3-day low of...
The Zacks Analyst Blog Highlights: Intercept, CymaBay, Amgen, Global Blood Therapeutics and ChemoCentryx
ChemoCentryx (CCXI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Companies In The News Are: TITN, HPE, SAFE, CCXI
Key highlights of the past week include regulatory and pipeline updates.
The biotech sector continues to grow as valuations are sky high, based on recent M&A's within the industry. 2019 started off with a boom with the announcement of two multi-billion-dollar deals valued at...
ChemoCentryx (CCXI) announces positive data pivotal study evaluating its lead candidate, avacopan, in patients with ANCA vasculitis, a rare disease affecting small blood vessels.
In recent trading, shares of ChemoCentryx, Inc. have crossed above the average analyst 12-month target price of $19.60, changing hands for $30.73/share.
Chemocentryx Inc (NASDAQ:CCXI) traded in a range yesterday that spanned from a low of $30.01 to a high of $36.88. Yesterday, the shares gained 279.8%, which took the trading range above the 3-day high...
ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at the 31st Annual Piper Jaffray Healthcare Conference on Wednesday,...
|Raymond James Sb-1 Equity Invesco ETF|
|Principal Healthcare Innovators Index|
|Micro-Cap Ishares ETF|
|Nasdaq Biotechnology Ishares ETF|
|Russell 2000 Growth Ishares ETF|